Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report)’s share price gapped down prior to trading on Friday . The stock had previously closed at $15.41, but opened at $14.95. Gyre Therapeutics shares last traded at $15.22, with a volume of 5,521 shares traded.
Gyre Therapeutics Trading Down 1.6 %
The stock has a market cap of $1.30 billion, a P/E ratio of -0.74 and a beta of 2.11. The stock has a 50 day moving average price of $17.31.
Hedge Funds Weigh In On Gyre Therapeutics
An institutional investor recently bought a new position in Gyre Therapeutics stock. Vanguard Group Inc. purchased a new position in Gyre Therapeutics, Inc. (NASDAQ:GYRE – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 198,097 shares of the company’s stock, valued at approximately $5,089,000. Vanguard Group Inc. owned approximately 7.82% of Gyre Therapeutics at the end of the most recent reporting period. 23.99% of the stock is owned by institutional investors.
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
See Also
- Five stocks we like better than Gyre Therapeutics
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Salesforce Stock Analysis: Deep Dive into CRM Market Performance
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.